How to Find a Clinical Trial in China

Search Chinese and international trial registries, read recruitment and eligibility details, and verify a China study site before arranging travel.

Key takeaways

A registry entry is a public record of a study. It does not recommend the treatment, offer you a place, or prove the site has an open slot today.
No single source covers everything, so search at least two: the Chinese Clinical Trial Registry, China’s drug-trial information platform, ClinicalTrials.gov and the WHO ICTRP each hold somewhat different records.[1][2]
Build your search from the diagnosis, subtype, stage, biomarker and city. A broad phrase like “advanced cancer trial China” mostly returns noise.
Before you book any travel, confirm with the site itself: still recruiting, which tests they need, what language support exists, what things cost, how follow-up works and who handles complications.

Full guide

Most patients start with a drug name they saw online. That is a fine lead, but on its own it gets you nowhere. The same drug can appear in studies of different diseases, treatment lines, combinations and phases, and a trial that shows “recruiting” worldwide may be closed at the one Chinese hospital you can actually reach.

So set a modest goal: assemble a short list of plausible studies, then hand it to the study sites for prescreening. Registries are where you find and compare records. Enrolling patients, or judging whether the experimental intervention beats standard care, is not what they do.

Start With a Search Profile

Before you open any registry, write down the details that decide eligibility:

Exact diagnosis and pathology subtype
Stage, whether the disease is measurable, and where it is right now
Relevant biomarkers and the test method
Previous treatments with dates, best response and why each one stopped
Major organ-function issues, infections or autoimmune disease
Current medicines and how well the patient functions day to day
Which cities the patient can realistically travel to

Search under the common disease name and under a more specific term. You might start with “non-small cell lung cancer,” then narrow by mutation, treatment line or histology. And never copy a biomarker out of a summary document; take it from the laboratory report itself.

Four Places to Search

The Chinese Clinical Trial Registry (ChiCTR) is a WHO-listed Primary Registry and displays the WHO trial-registration data set.[1] It goes well beyond drug trials — academic, procedural and other clinical research turns up here too.

For drug trials, the public record to check is China’s Drug Clinical Trial Registration and Information Disclosure Platform. According to the NMPA service page, trials conducted in China under the applicable drug-trial authorization process are registered and publicly disclosed through this platform.[2]

ClinicalTrials.gov holds study records from many countries, with filters for condition, location and recruitment status. One point from its patient guidance deserves emphasis: you cannot enroll through the website — the record exists so you can contact the study team.[3]

The WHO International Clinical Trials Registry Platform search portal pulls in records from data providers such as ChiCTR and ClinicalTrials.gov.[4] One study can carry more than one identifier or show up in several sources, so before you count two similar records as different trials, compare sponsor, protocol number, intervention and sites.

Read the Record Beyond the Title

Open the full record and write down the registry ID, sponsor, last update, study type, phase, intervention, comparator, recruitment status, inclusion and exclusion criteria, sites and contact details. Then check the individual Chinese facility. The overall study status alone tells you little.

ClinicalTrials.gov explains that the overall study shows as recruiting as long as at least one site is open, and that an “unknown” status can simply mean nobody has verified the record recently.[5] Sites also pause screening, fill a cohort or stop taking international patients, sometimes well before the public record catches up.

Phase tells you nothing about whether a treatment suits a particular person. Early-phase studies are usually about dose and safety; later-phase studies may put the intervention up against an established approach. A participant may benefit personally, or may not, and the researchers themselves may not yet know whether the intervention is better, worse or similar to regular care.[6]

Contact the Site With One Clear Message

Put the registry ID in the subject line and name the specific hospital site. Keep the message short: diagnosis, stage, key biomarker, previous treatment, current condition, country of residence — and one question. Is this site actively prescreening for this cohort?

Ask which records they need, whether remote prescreening is possible, who reviews the file and how long a first reply usually takes. Resist the urge to attach your entire medical archive. A one-page summary with the pathology, biomarker and latest imaging reports gives the team something they can work with; if they want DICOM files or additional documents, they will ask.

Two more things to settle early: can communication and consent happen in a language the patient understands, and does the site accept people who live abroad? Ask about the logistics too — repeated visits, long stays or local follow-up.

Prescreening Is Not Enrollment

Prescreening runs on paperwork and mainly catches obvious mismatches. Formal screening goes further: examination, laboratory tests, new imaging, pathology review, sometimes a washout period after previous treatment. Only when the study team confirms eligibility and the consent and enrollment process is finished is the patient actually enrolled.

China’s Good Clinical Practice rules put participants’ rights and safety ahead of scientific and social benefit, and name ethics review and informed consent as core protections.[7] Read the whole consent document. Ask about the purpose of the study, alternatives, randomization, placebo or control treatment, foreseeable risks, contraception requirements, privacy, injury arrangements, withdrawal and what happens after participation ends.

Joining is voluntary, full stop. The patient gets time to ask questions, and nobody should push for a signature before the study is understood.

Costs, Travel and Treatment Continuity

“The study drug is provided” covers the study drug, nothing more. Ask separately who pays for trial-required tests, standard-care medicines, hospital admission, treatment of complications, interpretation, accommodation, repeated travel and care after leaving China. Get the answers in writing from the site or sponsor.

If an intermediary says the patient “looks eligible,” that is no reason to stop effective treatment, start a washout period or book nonrefundable travel. Those calls belong to the study investigator and the treating clinician, working from the case and the protocol.

Keep the home oncologist in the loop throughout. If the patient turns out ineligible, withdraws or the study ends, someone still has to manage the disease, the prescriptions and the adverse effects.

Warning Signs

Slow down when someone cannot give you a registry identifier or protocol number; guarantees enrollment or benefit; asks for payment to “reserve” a trial place; discourages you from talking to your current doctor; refuses to name the institution and principal investigator; or dresses up an unapproved commercial treatment as a registered clinical trial.

Even a genuine registry number proves nothing about an intermediary’s other claims. Verify the site and the contact yourself, through the registry or the hospital’s official channel.

Medical disclaimer: This guide covers how to search for and verify clinical trials. It does not determine anyone’s eligibility, and it does not recommend an experimental treatment. Trial status, sites and criteria change, so confirm everything directly with the study team and talk the decision over with a qualified clinician.

Related guides

Understanding Clinical Trial Phases
Clinical Trial Eligibility: Why Patients Who Look Similar May Qualify Differently
Questions to Ask Before Joining a Clinical Trial in China
What Happens After a Clinical Trial Ends?

FAQ

Which registry should I search first?

Whichever source best matches the study type is a reasonable first stop, but check at least two. ChiCTR and WHO ICTRP cover a broad range; the Chinese drug-trial platform matters most for drug studies; ClinicalTrials.gov may list multinational protocols that include Chinese sites.

Does “recruiting” mean the hospital in China is accepting patients now?

Not necessarily. The overall status may be driven by another site entirely, and public records can lag. Contact the individual facility and quote the registry ID.[5]

Can I know from the online criteria whether I qualify?

The online criteria will show you obvious mismatches. The actual decision belongs to the study team, after it reviews every inclusion and exclusion criterion and completes the required screening.

Are clinical trials free?

Not automatically. Sponsors often pay for the investigational product and protocol-required procedures, but standard care, travel, lodging and complication care can be handled very differently from study to study. Ask for a written breakdown.

Can an agent guarantee a place in a trial?

No one can override the protocol or the investigator’s eligibility decision, whatever they claim. A guaranteed place, or a guaranteed benefit, is a serious warning sign.